Wells Fargo & Company Chinook Therapeutics, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$18.66 - $38.58 $352,879 - $729,586	18,911 Added 46.99%	59,152 $2.27 Million
Q1 2023 May 12, 2023	BUY	$21.53 - $26.8 $843,416 - $1.05 Million	39,174 Added 3671.42%	40,241 $931,000
Q4 2022 Feb 13, 2023	SELL	$18.63 - $27.35 $7,321 - $10,748	-393 Reduced 26.92%	1,067 $27,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $8,387 - $11,194	479 Added 48.83%	1,460 $29,000
Q2 2022 Aug 12, 2022	SELL	$12.59 - $18.8 $34,698 - $51,812	-2,756 Reduced 73.75%	981 $17,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $162,582 - $225,748	-13,526 Reduced 78.35%	3,737 $61,000
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $394,033 - $620,353	-36,860 Reduced 68.1%	17,263 $282,000
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $460,793 - $595,425	40,069 Added 285.11%	54,123 $690,000
Q2 2021 Aug 16, 2021	SELL	$13.6 - $18.98 $839,269 - $1.17 Million	-61,711 Reduced 81.45%	14,054 $198,000
Q1 2021 May 13, 2021	BUY	$14.17 - $19.11 $257,086 - $346,712	18,143 Added 31.49%	75,765 $1.18 Million
Q4 2020 Feb 09, 2021	BUY	$11.9 - $20.91 $685,701 - $1.2 Million	57,622 New	57,622 $914,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.